SCHEMBL713523

SCHEMBL713523

c1ccc(COCC2OCCO2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.52
TAAR1 Q96RJ0 1/20 0.47
LMNA P02545 1/20 0.47
DRD1 P21728 1/20 0.44
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
SLC6A2 P23975 1/20 0.42
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
CTSK P43235 1/20 0.42
POLB P06746 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.40
HRH4 Q9H3N8 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
PDE4D Q08499 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712254 0.93 TSHR (0.48) TSHRTAAR1LMNADRD1BCHE
SCHEMBL7197655 0.83 TSHR (0.56) TSHRTAAR1LMNAPOLBCA1
SCHEMBL23819499 0.82 TAAR1 (0.47) TSHRTAAR1LMNADRD1BCHE
SCHEMBL8935841 0.81 TSHR (0.48) TSHRTAAR1LMNASLC6A2POLB
SCHEMBL11633230 0.81 TAAR1 (0.46) TSHRTAAR1LMNADRD1BCHE
SCHEMBL713746 0.81 TSHR (0.44) TSHRTAAR1LMNADRD1BCHE
SCHEMBL712203 0.81 TSHR (0.44) TSHRTAAR1LMNADRD1BCHE
SCHEMBL711898 0.81 TSHR (0.44) TSHRTAAR1LMNADRD1BCHE
SCHEMBL10420228 0.79 LMNA (0.54) TSHRTAAR1LMNADRD1BCHE
SCHEMBL19559233 0.79 LMNA (0.54) TSHRTAAR1LMNADRD1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117570-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2023-04-20 US disclosed
US-20210054008-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2021-02-25 US disclosed
US-20200239502-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER MEDIVIR AB (SE) 2020-07-30 US disclosed
CN-107074826-A Dioxolane analogues of uridine for the treatment of cancer 美迪维尔公司 2017-08-18 CN disclosed
US-8124780-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-02-28 US disclosed
US-8124780-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-02-28 US disclosed
US-8124780-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-02-28 US disclosed
CN-101160306-B Benzimidazole compounds EISAI R&D MAN CO LTD 2011-11-02 CN disclosed
EP-1870409-B1 BENZIMIDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-05-12 EP disclosed
EP-1870409-B1 BENZIMIDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-05-12 EP disclosed
CN-101160306-A Benzimidazole compounds EISAI R&D MAN CO LTD (JP) 2008-04-09 CN disclosed
EP-1870409-A1 BENZIMIDAZOLE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-12-26 EP disclosed
EP-1870409-A1 BENZIMIDAZOLE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-12-26 EP disclosed
US-20070015782-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-18 US disclosed
US-20070015782-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-18 US disclosed
US-20070015782-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-18 US disclosed
US-20070010542-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-11 US disclosed
US-20070010542-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-11 US disclosed
US-20070010542-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-11 US disclosed
CN-1372564-A Process for selectively preparing anomers of 1-phosphorylated sugar derivatives and process for preparing nucleosides MITSUI CHEMICALS INC (JP) 2002-10-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239502-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NTPCR TSHR 682/4885TAAR1 624/4885LMNA 3139/4885
US-20070010542-A1 Benzimidazole compound HRH2, GIPR, HRH4 TSHR 603/4885TAAR1 930/4885LMNA 3526/4885
US-20230117570-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NT5C TSHR 641/4885TAAR1 668/4885LMNA 3107/4885
US-20210054008-A1 DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER ADORA3, DUT, NTPCR TSHR 682/4885TAAR1 624/4885LMNA 3139/4885
US-20070015782-A1 Benzimidazole compound HRH2, GIPR, HRH4 TSHR 603/4885TAAR1 930/4885LMNA 3526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.